CTT Pharma Adds Independent Director With NIH/NSF Experience
Rhea-AI Summary
CTT Pharmaceuticals Holdings (OTC PINK:CTTH) has appointed Dr. Katherine Cole as an Independent Director. Dr. Cole brings extensive experience in biomedical research and academic leadership, including a Ph.D. in Pathology from the University of Maryland School of Medicine and three years at the National Cancer Institute (NIH) studying anti-cancer mechanisms.
Dr. Cole's credentials include positions as a biomedical scientist, professor, and vice Provost and Dean across four universities. She has authored twenty-two peer-reviewed papers and holds two patents related to a human liver cell line. Her research has been supported by grants from the National Science Foundation and the Howard Hughes Medical Institute.
Positive
- Addition of highly qualified director with extensive research background
- Director brings NIH/NCI research experience in cancer therapeutics
- Director holds two patents related to human liver cell line
- Track record of securing NSF and Howard Hughes Medical Institute grants
Negative
- None.
News Market Reaction
On the day this news was published, CTTH declined 8.80%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
TAMPA, FL / ACCESS Newswire / February 5, 2025 / CTT Pharmaceuticals Holdings, Inc. (OTC PINK:CTTH) is pleased to announce adding Dr. Katherine Cole as an Independent Director for CTT. Dr. Cole. a Ph.D. in Pathology from the University of Maryland School of Medicine. Following her Ph.D. she spent 3 years at the National Cancer Institute(NCI) at the National Institutes of Health(NIH) where she spent her time focused on anti-cancer mechanisms of novel chemotherapeutic compounds. From there Dr. Cole worked at four different universities as a Biomedical scientist, professor, and eventually as a vice Provost and Dean. She has published twenty-two peer reviewed papers and has been granted two patents related to a human liver cell line. Dr. Cole has been awarded many notable grants including grants from the National Science Foundation(NSF) and the Howard Hughes Medical Institute. Dr. Cole's professional development as a scientist, an educator and a university-level administrator has provided her with a distinct scientific perspective and an ability to critically analyze meaningful data and research design. Her Ph.D. in Pathology from the University of Maryland School of Medicine and postdoctoral experience at the NIH/NCI in cancer research have positioned her well to not only understand the science behind this technology, but the impact from a human pathological perspective. CTT is honored to have Dr. Cole on our team and looks forward to her contributions.
About CTT Pharmaceuticals Holdings, Inc.
CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and deliver drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options and offer better bioavailability.
Investor Relations - 813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
Who is the new Independent Director appointed to CTT Pharmaceuticals (CTTH)?
What is Dr. Katherine Cole's research background at the National Institutes of Health?
How many peer-reviewed papers has CTTH's new director published?
What major grants has CTTH's new Independent Director received?
